NCT05901259Recruiting
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 29 May 2023
- Start date
- 18 Feb 2026
- Primary completion date
- 1 Aug 2027
- Lead sponsor
- Otto Bock Healthcare Products GmbH
- Diseases
- Stroke, Multiple sclerosis
- NCT number
- NCT05901259
What you commit to
- Study type: Observational
- Planned participants: 200
- From 18 Feb 2026 to the primary completion date, 1 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Being introduced to any new medication affecting the neuromuscular activity during the study period
- Using botulinum toxin \<3 month before or during the study period
Other
- Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit
- Subjects \<100 cm and \<13 kg
- Subjects \>205 cm and \>115 kg
Who the study is looking for
- Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms.
- Diagnosed \>6 months prior to inclusion in case of MS or stroke as well as \>1 month prior to inclusion in the case of fibromyalgia.
- Give written informed consent
- Cognitively able to understand and follow verbal and/or written instructions
- A minimum age of 2 years
Age in the registry: 2 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ottobock Care Sverige Coordinator of this site? Confirm its status | Bergshamra | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.